Drug
HMPL-453
HMPL-453 is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_1
4
67%
Ph phase_2
2
33%
Phase Distribution
4
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(3)
Detailed Status
unknown3
Recruiting1
Terminated1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 14 (66.7%)
Phase 22 (33.3%)
Trials by Status
recruiting117%
terminated117%
completed117%
unknown350%
Recent Activity
1 active trials
Showing 5 of 6
recruitingphase_2
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
NCT04353375
completedphase_1
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
NCT05930119
unknownphase_1
HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
NCT05173142
unknownphase_2
HMPL-453 in Advanced Malignant Mesothelioma
NCT04290325
unknownphase_1
A Study of HMPL-453 in Patients With Advanced Solid Malignancies
NCT03160833
Clinical Trials (6)
Showing 6 of 6 trials
NCT04353375Phase 2
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
NCT05930119Phase 1
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
NCT05173142Phase 1
HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
NCT04290325Phase 2
HMPL-453 in Advanced Malignant Mesothelioma
NCT03160833Phase 1
A Study of HMPL-453 in Patients With Advanced Solid Malignancies
NCT02966171Phase 1
A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6